Sandra De Meyer

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Turnhoutseweg 30, B2340 Antwerpen, Beerse, Belgium
    Virol J 11:93. 2014
  2. doi request reprint Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    S De Meyer
    Janssen Infectious Diseases BVBA, B2340 Beerse, Belgium
    J Viral Hepat 20:395-403. 2013
  3. doi request reprint Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Hepatology 56:2106-15. 2012
  4. doi request reprint Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    Sandra M J De Meyer
    Clinical Virology Department, Tibotec BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Acquir Immune Defic Syndr 49:179-82. 2008
  5. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
  6. doi request reprint Resistance profile of darunavir: combined 24-week results from the POWER trials
    Sandra De Meyer
    Tibotec BVBA, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    AIDS Res Hum Retroviruses 24:379-88. 2008
  7. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
  8. ncbi request reprint Design of HIV-1 protease inhibitors active on multidrug-resistant virus
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1965-73. 2005
  9. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
  10. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011

Collaborators

Detail Information

Publications20

  1. pmc Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Turnhoutseweg 30, B2340 Antwerpen, Beerse, Belgium
    Virol J 11:93. 2014
    ..Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus (HCV) early viral kinetics in treatment-naïve patients infected with genotype 4 (G4) HCV...
  2. doi request reprint Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    S De Meyer
    Janssen Infectious Diseases BVBA, B2340 Beerse, Belgium
    J Viral Hepat 20:395-403. 2013
    ..Although viral breakthrough with resistance occurred in patients receiving telaprevir monotherapy, half of these patients achieved an SVR upon addition of peginterferon/ribavirin highlighting the importance of combination therapy...
  3. doi request reprint Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Hepatology 56:2106-15. 2012
    ..Resistant variants were no longer detectable by study end (median follow-up of 11 months) in 58% of non-SVR patients...
  4. doi request reprint Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    Sandra M J De Meyer
    Clinical Virology Department, Tibotec BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Acquir Immune Defic Syndr 49:179-82. 2008
    ..The objective of this study was to examine the potential of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV-infected, treatment-experienced patient population with no baseline darunavir resistance-associated mutations (RAMs)...
  5. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
    ....
  6. doi request reprint Resistance profile of darunavir: combined 24-week results from the POWER trials
    Sandra De Meyer
    Tibotec BVBA, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    AIDS Res Hum Retroviruses 24:379-88. 2008
    ....
  7. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
    ..60%, respectively). ETR was equally effective in suppressing viral replication in patients infected with HIV-1 subtype B or various HIV-1 non-B subtypes...
  8. ncbi request reprint Design of HIV-1 protease inhibitors active on multidrug-resistant virus
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1965-73. 2005
    ..Crystal structures and molecular modeling were used to rationalize the broad spectrum profile resulting from the extension into the P2' pocket of the HIV-1 protease...
  9. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
    ....
  10. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011
    ..The primary outcome measure was non-inferiority of DRV/r versus LPV/r (HIV type-1 [HIV-1] RNA<50 copies/ml). Here, a detailed 96-week resistance analysis is presented...
  11. doi request reprint Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients
    Erkki Lathouwers
    Janssen Infectious Diseases Diagnostics BVBA, Beerse, Belgium
    Antivir Ther 18:289-300. 2013
    ....
  12. doi request reprint Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study
    Lotke Tambuyzer
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antivir Ther 21:317-27. 2016
    ..2 mg/kg and a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional enfuvirtide/raltegravir) in a Phase II, open-label, multicentre trial (PIANO)...
  13. doi request reprint Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study
    Inge Dierynck
    Janssen Infectious Diseases, Beerse, Belgium
    J Infect Dis 210:1871-80. 2014
    ....
  14. pmc In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants
    Thierry Verbinnen
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antimicrob Agents Chemother 59:7548-57. 2015
    ..0) or conferred low-level resistance to simeprevir in vitro (FC, >2.0 and <50). Treatment failure with a simeprevir-based regimen was associated with emergence of high-level-resistance variants (FC, ≥ 50)...
  15. doi request reprint Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE
    Veerle Van Eygen
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    J Med Virol 88:798-806. 2016
    ..DS at failure showed emerging NNRTI resistant minority variants in seven rilpivirine VFs who had no detectable NNRTI RAMs by PS...
  16. doi request reprint Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010
    ....
  17. doi request reprint Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir
    Bart Fevery
    Janssen Infectious Diseases BVBA, Beerse, Belgium Electronic address
    J Clin Virol 72:133-40. 2015
    ..Monitoring HCV RNA levels during treatment is an important tool for managing protease-inhibitor-based regimens, and different assays used in clinical practice can impact treatment decisions...
  18. doi request reprint Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
    Oliver Lenz
    Janssen Infectious Diseases BVBA, Beerse, Belgium Electronic address
    J Hepatol 62:1008-14. 2015
    ..Baseline NS3 polymorphisms in all patients and emerging mutations in patients who failed to achieve sustained virologic response (SVR) with simeprevir plus peginterferon/ribavirin (PR) in Phase IIb/III studies are described...
  19. ncbi request reprint Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1813-22. 2005
    ..Absorption studies in animals indicated that TMC114 has pharmacokinetic properties comparable to currently approved HIV-1 protease inhibitors...
  20. doi request reprint Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012
    Erkki Lathouwers
    1Janssen Infectious Diseases BVBA, Beerse, Belgium
    AIDS Res Hum Retroviruses 31:628-35. 2015
    ..Furthermore, the prevalence of phenotypic resistance to darunavir was lower than all other PIs. ..